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INTRODUCTION
Shwachman Diamond Syndrome (SDS, also known as Shwachman-Bodian-Diamond Syndrome) is a rare multi-organ syndrome characterized by exocrine pancreatic insufficiency, skeletal abnormalities, and multilineage hematopoietic dysfunction 1 2 3 4 .
The most common hematopoietic abnormality is intermittent neutropenia, and occurs in approximately 95% of SDS patients 3 . While neutropenia is thought to be the major cause of increased susceptibility to recurrent infections in SDS patients, defects in Band T-lymphocyte function and survival have been reported 5 . SDS patients occasionally display a variety of additional hematopoietic phenotypes, including anemia, thrombocytopenia, and trilineage cytopenia. As with other bone marrow failure syndromes, SDS markedly increases the risk for the development of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (reviewed in 6 ).
SDS is inherited in an autosomal recessive fashion. In a landmark study, Boocock et al. 7 reported mutations of the Shwachman-Bodian-Diamond Syndrome gene (SBDS) in approximately 90% of SDS patients, a finding that has been confirmed in subsequent genetic analyses 8 9 10 11 . The most common mutations (183-184TA>CT and 258+2T>C) introduce early stop codons that truncate the majority of the SBDS protein. The remaining mutations are missense, and are distributed throughout the SBDS gene. The genotype of approximately 60% of SDS patients is compound heterozygosity for the 183-184TA>CT and 258+2T>C mutations, and most patients carry at least one of these truncation alleles 7 9 10 . These observations form the basis of the hypothesis that loss of For personal use only. on April 15, 2017 . by guest www.bloodjournal.org From SBDS function is the primary molecular cause of SDS. However, it remains a possibility that the common 183-184TA>CT and 258+2T>C alleles produce truncated SBDS protein with residual or neomorphic activity. Since these N-terminal truncation products have not been studied in vivo, their pathogenic potential is unknown.
SBDS encodes a highly conserved, novel protein of unknown cellular function with homologs from archaea to mammals. Human SBDS protein localizes to the cytoplasm and nucleus with nucleolar accumulation 12 . Global gene expression studies of the yeast SBDS homolog indicate that is coordinately regulated with RNA processing genes in Sacharomyces cerevisiae 13 . Finally, the archaeal crystal structure reveals that SBDS has a nucleic acid binding groove 14 15 . Collectively, these data support an existing hypothesis that SBDS functions in the processing and/or transport of RNA. Consistent with this hypothesis, it recently has been reported that SBDS associates with 28S ribosomal RNA in mammalian cells 16 Moreover, a recent study demonstrated that the yeast SBDS ortholog Sdo1 is required for the recycling of the nucleolar shuttling factor Tif6 from pre-60S ribosomes 17 . There also is evidence suggesting that SBDS may play an important role in cell motility and/or chemotaxis 18 19 . In accordance with this observation, defects in mobility and chemotaxis are well documented in circulating neutrophils isolated from SDS patients 18, [20] [21] [22] [23] [24] .
While it is clear that SBDS mutations are associated with SDS, experimental models have not yet been generated to study their necessity and/or sufficiency in the development of hematopoietic phenotypes. A recent study has demonstrated a critical role for Sbds in development, as complete loss of Sbds in mice results in early lethality at 
MATERIALS AND METHODS

Mice
Wild-type C57BL/6 mice and a congenic strain of C57BL/6 that have the Ly5.1 gene (B6.SJL-PtPrc * Pep3 b BoyJ) were obtained from Jackson Laboratories (Bar Harbor, ME).
All mice were reared in a specific-pathogen free facility and monitored daily by the veterinary staff. All animal work was approved by the Washington University Animal Studies Committee.
Lentiviral constructs
Three pairs of antisense oligonucleotides were designed to generate short hairpin RNA (shRNA) complementary to the Mus musculus Sbds mRNA transcript (Genbank NCBI accession NM_023248, here ATG start codon assigned +1 --Sbds RNAi A: +187 -+206; Sbds RNAi B: +187 -+206, with G::U wobble engineered at +187; Sbds RNAi C: +71 -+ 90 with G::U wobble at positions +71 and +83. Sequences reported in Fig. 1A) . A control shRNA with a non-specific nucleotide sequence was also designed (scramble RNAi, Fig.   1A ). Basic local alignment search tool analysis 26 verified that these oligonucleotides were specific for Sbds, and that the scramble RNAi primers were not homologous to any region of the mouse genome. Annealed oligonucleotides were directionally cloned into the genomic lentiviral vector pFCYsi (generous gift from J. Millbrandt). pFCYsi was generated by replacing the internal ribosomal entry sequence-yellow fluorescent protein (YFP) cassette in the lentiviral pFSPsi vector 27 with cytomegalovirus (CMV)-YFP. 
Generation of high-titre lentivirus
293T cells were transfected with the packaging plasmid p8.9, viral envelope plasmid pMD.G 28 , and genomic plasmid pFCYsi by calcium phosphate DNA precipitation 29 30 .
Viral supernatant was collected 48 and 72 hours post-transfection and concentrated by centrifugation at 76,000 x g for 2 hours at 4˚C (SW32 rotor in Optima LE-80K ultracentrifuge, Beckman Coulter, Palo Alto, CA). 
Peripheral blood, spleen and bone marrow sampling
Immunoblotting
Immunoblotting for Sbds was performed as previously described 9 . The following primary antibodies were used: rabbit anti-Sbds 9 (1:750) and mouse anti--actin (1:10,000; Sigma Aldrich, St. Louis, MO). Sbds protein was measured semiquantitatively by spot-densitometry.
Murine hematopoietic cell transduction
Bone marrow cells were incubated with the PE-lineage antibody panel. After washing, cells were incubated with anti-PE colloid, and lineage + cells were depleted using the AutoMacs system (Miltenyi Biotec, Auburn, CA). The lineage -fraction was collected and cultured overnight in -MEM containing stem cell factor (SCF, 100 ng/mL), interleukin-3 (10 ng/mL), thrombopoietin (10 ng/mL), and Flt3 ligand (50 ng/mL) (PeproTech, Rocky Hill, NJ). Cells were transduced with virus 12 and 36 hours later at the indicated multiplicity of infection (MOI) by spinoculation 31 (centrifugation of cells plus virus at 1000 x g for 90 minutes at 30˚C).
Bone marrow transplantation
Syngeneic C57BL/6 recipients were exposed to a single dose of 1000 cGy from a 137 Cesium source at a rate of 95 cGy per minute 12-24 hours prior to transplantation.
Unsorted, transduced bone marrow cells (5 x 10 5 ) were injected into the tail vein of each irradiated recipient. At least four mice per experimental group were transplanted; results from two to four independent transplants were analyzed separately and pooled, unless otherwise noted. Antibiotics (trimethoprim-sulfamethoxazole; Alpharma, Baltimore, MD) were administered in the drinking water for 2 weeks after transplantation.
Secondary transplants were performed as described, except 2 x 10 6 unfractionated bone marrow cells from primary donors 6 months post-transplantation were infused into the tail vein of each irradiated secondary recipient. 
Progenitor colony-forming assays
CFU-C (Colony-Forming Units-Complete
CFU-G (Colony-Forming Units-Granulocyte). c-Kit
CFU-GM (Colony-Forming Units-Granulocyte/Macrophage). c-Kit + , lineage -cells
(1,000) were plated in MethoCult M3231 supplemented with 20 ng/mL GM-CSF (PeproTech, Rocky Hill, NJ).
In each case, colonies containing at least 50 cells were scored on day 10 of culture.
Homing assays
Donor bone marrow cells were infected with lentivirus as described above. A portion 
Progenitor Transmigration Assay
Transwell migration of HPC in response to CXCL12 (or stromal derived factor-1) was performed, essentially as described previously 32 . In brief, transduced unsorted lineagebone marrow cells (15,000) were loaded into the upper chamber of 5-m pore transwell inserts (Corning Life Sciences, Acton, MA). Recombinant human recombinant CXCL12 was added to the lower chamber at a concentration of 500 ng/ml and the chamber incubated for 4 hours at 37°C. The number of YFP -and YFP + CFU-C in the original cell preparation and in the migrated cell population was determined.
Granulocytic differentiation in vitro
Growth of primary murine hematopoietic cells in vitro was analyzed as previously described 33 . In brief, c-Kit + , lineage -cells were cultured in -MEM containing SCF and G-CSF (100 ng/mL each). After seven days in culture, cells were sorted based on YFP expression and manual differentials performed on Wright-Geimsa stained cytospin preparations.
Data analysis
Unless otherwise noted, all data are presented as the mean + standard deviation. A 2-tailed student t test was applied to individual data sets to determine statistical significance. Survival curves were analyzed using the log rank test. and the CMV promoter drives expression of YFP, was utilized to determine whether Sbds expression could be inhibited. Lentiviruses containing the lentiviral vector alone (FCYsi.empty), a non-specific shRNA control (scramble RNAi) and three independent shRNA directed against the Sbds mRNA were designed (Sbds RNAi A-C; Fig. 1A ).
High-titre lentivirus was generated, and the ability to reduce Sbds expression using (Fig. 1E) .
Sbds RNAi impairs the granulocytic differentiation of primary myeloid cells in vitro.
Neutropenia is the most common hematopoietic defect in SDS patients 3 . To determine the effect of reduced murine Sbds expression on granulopoiesis, transduced hematopoietic progenitors were grown in liquid culture containing G-CSF and SCF, conditions that support granulocytic differentiation. As expected based on previous studies 33 , FCYsi.empty and scramble RNAi transduced cells expanded 42 + 3.2-fold and 38 + 19-fold, respectively ( Fig. 2A) . A similar fold-expansion was noted in cultures of Sbds RNAi transduced cells (38 + 13) . Of note, the number of apoptotic cells, as measured by surface Annexin-V expression, was small and comparable in all cultures (data not shown). To further assess the effect of Sbds inhibition on the cytokine responsiveness and growth of myeloid progenitors, c-Kit + lineage -cells were plated into methylcellulose cultures immediately after transduction (Fig. 2B ). Inhibition of Sbds had no effect on the number of colonies formed in response to a cocktail of myeloid cytokines (CFU-C) or G-CSF alone (CFU-G) (Fig. 2B) .
To determine the effect of Sbds RNAi on granulocytic differentiation, YFP + cells were re-sorted after seven days in culture and leukocyte differentials performed in a blinded fashion. As expected, the majority of cells in both the FCYsi.empty and scramble RNAi cultures were mature (band or segmented) neutrophils (60 + 6.9% and 60 + 13%, respectively), the remaining cells were granulocytic precursors (Fig. 2C) . The (Fig. 3A) . Importantly, in each cohort of transplant animals the transduction efficiency was similar between all three experimental groups (average of 43 + 26%). Unsorted, transduced bone marrow cells (containing both transduced and wild-type cells) were transplanted into syngeneic recipients and survival was assessed (Fig. 3B) . While the majority of mice transplanted with cells transduced with the FCYsi.empty and scramble RNAi controls survived the engraftment period, short-term survival was significantly reduced in mice transplanted with Sbds RNAi transduced cells (Fig. 3B) . Whereas advanced post-mortem changes precluded analysis of most mice, we were able to characterize hematopoiesis in two morbidly ill Sbds RNAi transplant mice at 17 and 19 days post-transplantation.
Compared with control mice, Sbds RNAi transplant mice displayed tri-lineage aplasia.
For and platelets [33 ± 25 x 10 6 /mL (FCYsi.empty) versus 21 ± 6 x 10 6 /mL (Sbds RNAi)] was observed, although differences were not significant due to a paucity of animals available for analysis.
In an attempt to rescue early lethality, the bone marrow transplantation experiments were repeated with a reduced MOI of 10:1. At this MOI, the average transduction efficiency of c-Kit + , lineage -cells was reduced to 13 + 1.2%, and again was similar in all groups. 89% of transplanted mice survived at least 6 months. Short-term (Fig. 3C) . In contrast, engraftment of Sbds RNAi transduced cells was significantly reduced by 3 weeks post-transplant, to only 0.6 of the pre-transplant transduction efficiency, a 55% decrease compared to controls (Fig. 3C) . Collectively, The percentage of YFP + CFU-C pre-transplantation and in the bone marrow posttransplantation was determined, and the ratio of post-to pre-transplant YFP + CFU-C was calculated as a measure of homing efficiency (Fig. 4) . Importantly, the total number of progenitors that homed to the bone marrow compartment was similar among the three experimental groups (data not shown). In progenitors transduced with FCYsi.empty and scramble RNAi controls, the ratio of YFP + CFU-C pre-transplant to post-transplant was near 1 [1.1 ± 0.08 and 1.1 ± 0.10, respectively (Fig. 4B) ], indicating that homing was not effected by the lentiviral transduction procedure. In contrast, this ratio was significantly reduced in Sbds RNAi transduced cells to 0.71 ± 0.09 (Fig. 4B ).
These data show that reduction of Sbds inhibits homing of hematopoietic progenitors to the bone marrow.
A chemotaxis defect in SDS hematopoietic cells has been reported 18 . Since CXCL12 has been implicated in HPC homing to the bone marrow 34 (Fig. 5A) . Importantly, persistent reduction of Sbds in sorted YFP + cells was documented at both three and six months post-transplant. Compared to the scramble RNAi control, Sbds RNA expression in sorted YFP + spleen cells at three to six months after transplantation was reduced by 68.3% (Fig.5B) .
Granulopoiesis in mice stably reconstituted with transduced bone marrow cells was next examined. Three months post-transplantation, Sbds RNAi did not significantly reduce the number of circulating granulocytes (Gr-1 + ), when compared to FCYsi.empty and scramble RNAi controls (Fig. 5C ). Since the bone marrow is the major site of granulopoiesis, the effect of Sbds RNAi on granulocyte development was examined in (Fig. 5E ). Additional analysis demonstrated that this reduction in CFU-C number was due to a decrease in CFU-GM colonies; in contrast, no differences were observed in CFU-G or erythroid (BFU-E) colony numbers (Fig. 5E) . Interestingly, the distribution of YFP + cells into Gr-1 high (mature) and Gr-1 low (precursors) populations was similar, suggesting that there was no (Fig. 5C ). In contrast, in the bone marrow, which contains mostly naïve and immature B-lymphocytes, the contribution of Sbds RNAi transduced cells to the B-lymphocyte lineage was comparable to control cells (Fig.   5D ). Moreover, the capacity of Sbds RNAi transduced cells to form pre-B CFU was normal (Fig. 5E ). These data raise the possibility that inhibition of Sbds results in impaired survival and/or trafficking of mature B-cells, but does not affect B-cell differentiation in vivo. Fig. 6A)] . Strikingly, Sbds RNAi significantly impairs secondary engraftment, as this ratio is reduced to 0.10 + 0.09, which represents an 85% reduction compared scramble RNAi controls (Fig. 6A) . Likewise, a reduction in the ratio of YFP + cells in recipient bone marrow:YFP + cells in donor bone marrow was observed in Sbds RNAi secondary transplant recipients (0.25+0.04) compared to scramble RNAi controls (2.04+1.4) (Fig. 6B) . Since essentially all (98%) SDS patients with documented SBDS mutations carry this allele 7 8 9 10 , it is interesting to speculate that this residual activity is essential for survival. Since there are no studies addressing the functional impact of possible neomorphic activity of N-terminal SBDS fragments, the precise molecular pathophysiology of SDS remains unclear.
Reduction in Sbds inhibits
In the present study, Sbds RNA and protein expression was reduced by lentiviral-mediated RNAi to approximately 15% that of normal controls. While it is difficult to accurately estimate the percentage of full-length SBDS protein that would generated from read-through events in vivo, it appears that the level of residual SBDS protein in cell lines derived from patients with SDS (as discussed above) may be significantly lower than 15%. Even so, some of the hematopoietic abnormalities documented in patients with SDS were recapitulated using our RNAi strategy.
Specifically, we observed defects in granulopoiesis, hematopoietic engraftment, and Blymphocyte homeostasis. Thus, this study provides the first experimental evidence that SBDS function is required for normal mammalian hematopoiesis.
Impaired granulopoiesis is a defining feature of SDS. Chronic or intermittent neutropenia is present in most patients. Bone marrow findings in patients with SDS are highly variable, ranging from normal to granulocyte hypoplasia to granulocyte hyperplasia with a maturation arrest 3 . On the other hand, the number of myeloid progenitors in the bone marrow is nearly uniformly decreased in SDS patients 38 39 40 41 .
Interestingly, Dror and Freedman 41 reported that this decrease in myeloid progenitors is secondary to both a cell intrinsic defect in hematopoietic cells and a defect in bone marrow stromal cells. Consistent with clinical findings in patients with SDS, we demonstrate that the number of myeloid progenitors was significantly reduced in mice reconstituted with Sbds RNAi transduced bone marrow cells. The hypothesis that increased susceptibility to apoptosis is necessary for the pathogenesis of impaired granulopoiesis in SDS is controversial. Dror and Freedman 42 showed that both granulocytic cells and myeloid progenitors obtained from SDS patients displayed increased susceptibility to Fas-mediated apoptosis. Likewise, in 32Dcl3 cells exhibiting lentiviral-mediated knockdown of Sbds, an increase in Annexin V + cells was observed in culture 43 . In contrast, Kuijpers et al. 11 reported no increase in apoptosis in circulating neutrophils in patients with SDS. In the present study, we show that reduced Sbds expression in myeloid progenitor cells results in a cell intrinsic delay, but There is accumulating evidence that cell motility and/or migration defects might play an important role in the pathogenesis of SDS. It is well established that neutrophils isolated from SDS patients exhibit cell motility and chemotactic deficiencies, likely due to cytoskeletal and/or microtubular abnormalities 5 18 23 24 20 21 .
Furthermore, a recent study of the social ameobae Dictyostelium discoideum has demonstrated a potential role for the Sbds homolog in pseudopod-based cell locomotion 19 . While a role for Sbds in motility has not yet been directly described in neutrophils, it is interesting to note that a rare subset of patients with X-linked severe congenital neutropenia carry a mutation in the Wiskott-Aldrich syndrome gene that abolishes the autoinhibition of Wiskott-Aldrich syndrome protein (WASP). This deregulation of WASP leads to constitutive actin polymerization and the subsequent destabilization of the cytoskeleton, and is thought to reduce cell motility/chemotaxis 45 .
In the present study, we examined the effect of Sbds inhibition on CXCL12-induced chemotaxis of HPC, since this property has been implicated in homing to the bone marrow 34 35 36 37 . Surprisingly, CXCL12-induced migration of Sbds RNAi transduced HPC was comparable to control cells. Further study will be required to determine if Sbds regulates HPC migration in response to other stimuli or if, in fact, defects in motility in the absence of Sbds are non-cell intrinsic.
In summary, we show that inhibition of Sbds expression in primary murine hematopoietic cells by RNAi reproduces many of the hematopoietic defects observed in Sbds mRNA relative to β-actin mRNA expression in mice three months after transplantation was measured by real time RT-PCR (n=2). The contribution of YFP + granulocytes and B-lymphocytes to the peripheral blood at three months (C) and the bone marrow at six months (D) was measured. Data were normalized to the pre-transplant transduction efficiency. (E) The ability of YFP + bone marrow cells to generate CFU-C and pre-B CFU (6 months after transplantation), and CFU-GM, CFU-G, and BFU-E (3 months after transplantation) colonies was measured (n= 3-5). *p<0.05, **p<0.01, ***p<0.005. 
